StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Travere Therapeutics's price to sales ratio was 8.3× on Nov 11, 2026, against 7.3× a year earlier. Over the last 5 years it ranged from 2.9× to 13.2×, with a median of 7.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.3×+0.4
2025Dec 31, 20257.8×+1.2
2024Dec 31, 20246.7×+1.5
2023Dec 29, 20235.2×−4.6
2022Dec 30, 20229.8×+1.3
2021Dec 31, 20218.6×+1.4
2020Dec 31, 20207.2×+3.6
2019Dec 31, 20193.5×−2.2
2018Dec 31, 20185.7×+0.2
2017Dec 29, 20175.5×−0.1
2016Dec 30, 20165.6×−2.7
2015Dec 31, 20158.3×–

More Travere Therapeutics figures

See a number that looks wrong?